Merck & Co. vs Pfizer vs Amgen and 1 More Revenue Comparison
Compare financial metrics side-by-side using real SEC EDGAR data
Revenue Comparison
Chart: Revenue Comparison. Values in USD_BILLIONS. In Q1 2026: Merck & Co. 16.286, Pfizer 14.451, Amgen 8.618, Roche 17.5245.
* Roche reports semi-annually. Values are evenly split across both quarters within each half.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Merck & Co., Pfizer, Amgen, Roche.| Metric | Merck & Co. | Pfizer | Amgen | Roche |
|---|---|---|---|---|
| Market Cap | $320.84B | $142.76B | $209.21B | $352.55B |
| Revenue | $16.29B | $14.45B | $8.62B | $35.05B |
| Cost of Revenue | $2.94B | $4.73B | $2.74B | $9.21B |
| Gross Profit | $13.34B | $9.72B | $5.87B | $25.84B |
| Operating Income | $-1.88B | $4.03B | $2.67B | $10.90B |
| Net Income | $-4.24B | $2.69B | $1.82B | $7.93B |
| R&D Expense | $12.56B | $2.63B | $1.72B | $8.35B |
| Earnings Per Share | -$1.72 | $0.47 | $3.34 | $1.23 |
| Gross Margin | 81.9% | 67.3% | 68.2% | 73.7% |
| Operating Margin | -11.6% | 27.9% | 30.9% | 31.1% |
| Net Profit Margin | -26.0% | 18.6% | 21.1% | 22.6% |
| Free Cash Flow | $2.93B | $2.18B | $1.48B | $6.46B |
| Cumulative Free Cash Flow | $245.22B | $356.40B | $165.69B | $305.80B |
| Operating Cash Flow | $3.92B | $2.62B | $2.19B | $8.28B |
| Cash & Equivalents | $5.33B | $1.70B | $12.04B | $6.13B |